Bristol myers Squibb (BMY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BMY Annual Cash Flow →
This page allows investors to follow Bristol myers Squibb's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
6 Months
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income5,994.00
Depreciation & amortization1,188.00
Amortization of Other Assets943.00
Impairment charges0.00
Impairment of Long-Lived Assets to be Disposed of849.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories22.00
Stockbased compensation0.00
Restructuring Charges162.00
Share-based Compensation281.00
Prepaid expenses85.00
Sale of businesses0.00
Deferred Income Tax Expense Benefit Including Discontinued Operations-
Proceeds From Collaboration-
Pensionsettlementsandamortization-
Divestituregainsandroyalties-
Divestiture Gains And Royalties-34.00
Assetacquisitioncharge-
Income taxes0.00
Equity Method Investment, Realized Gain (Loss) on Disposal248.00
Increase (Decrease) in Receivables-504.00
Increase (Decrease) in Accounts Payable380.00
Increase (Decrease) in Other Accrued Liabilities-3,135.00
Pension contribution0.00
Insurance recoverable0.00
Other Working Capital850.00
Other Noncash Income (Expense)-22.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-2,844.00
Discontinued operations0.00
Net Cash flow from Operating Activities4,497.00
Investing Activities
Capital Expenditures-652.00
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities964.00
Payments to Acquire Marketable Securities-2,851.00
Proceeds from other investments0.00
Divestitureandotherproceeds-
Proceeds From Sale Of Equity Securities Fv Ni391.00
Divestiture And Other Proceeds312.00
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Purchases of Investments0.00
Purchases of non-current assets0.00
Payments to Acquire Businesses, Net of Cash Acquired-156.00
Proceeds from Sale of Equity Method Investments0.00
Proceeds from Divestiture of Businesses, Net of Cash Divested508.00
Sale of assets0.00
Notes receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net442.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-1,745.00
Financing Activities
Short-term debt Net191.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-1,720.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock0.00
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.00
Other net-91.00
Proceeds Termination Interest Rate Swap-
Interestrateswapcontractterminations-
Proceeds From Issuance Of Shares Under Share Based Compensation Plans-
Payments For Proceeds From Stock Option Exercises And Other Adjustments-98.00
Dividends paid to minority interests0.00
Dividends paid-2,570.00
Net Cash Flow from Financing Activities-4,190.00
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow3,845.00
Total Cash Flow-1,496.00
4 historic quarters locked

Sign in to unlock the full Bristol myers Squibb cash flow history.

About Bristol Myers Squibb Co Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: July 30, 2026
  • Source: bmy-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000014272-26-000020

Figures are derived from filed reports and may be restated. Historical data is subject to revision.